Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
ID: 338773Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338773

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE), aimed at soliciting R01 research project proposals. This initiative focuses on utilizing advanced cancer biology methods to investigate the effects of various radiation types used in radionuclide-based therapies on normal tissues and tumor cells, explicitly excluding clinical trial applications. The STRIPE initiative is significant for advancing therapeutic strategies in cancer treatment through innovative preclinical research, with a maximum funding amount of $500,000 per year available for up to five years. Interested applicants can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with proposals due by May 7, 2025.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-139.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) for the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE). The aim is to solicit R01 research project proposals focused on utilizing advanced cancer biology techniques to study the impacts of various radiation types in radionuclide-based therapies on normal tissues and tumors. This funding opportunity specifically excludes clinical trial applications. Key information includes eligibility criteria for a diverse range of applicants from academic institutions to for-profit organizations, with a maximum award budget of $500,000 per year for up to five years. The FOA encourages innovative preclinical research in areas such as synthetic lethality, development of pharmacodynamic biomarkers, and understanding the impacts of radionuclide therapies on cancer biology and normal cells. Non-responsive applications include those lacking testing of radionuclide agents or focusing solely on computational models without experimental validation. The review process will assess each proposal based on significance, innovation, and approach among other criteria. The STRIPE initiative reflects NIH's commitment to advancing therapeutic strategies for cancer treatment through collaborative preclinical research efforts.
    Similar Opportunities
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support preclinical research focused on the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and their microenvironments, encouraging collaborative applications that explore innovative therapeutic strategies. The maximum budget for successful proposals is set at $275,000 in direct costs over a two-year period, with applications due by various dates until October 16, 2025. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)" aimed at advancing research in cancer treatment through innovative synthetic vulnerabilities linked to radiation therapy. This initiative seeks R01 research projects that explore actionable vulnerabilities in tumors that can be paired with radiation responses, with the goal of developing effective anticancer strategies and integrating them into precision medicine. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and governmental organizations, with applications due by 5 PM local time on September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations" (PAIRS) to support R21 research projects focused on identifying actionable vulnerabilities in tumors that respond to radiation therapy. The objective is to develop innovative radiation-synthetic combination strategies that enhance anticancer treatments, with applications ranging from pre-clinical research to early clinical trials. This initiative underscores the significance of precision medicine in oncology and encourages collaborative efforts to address complex cancer challenges. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 over two years, and applications are due by September 7, 2025. For more information, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html.
    Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 grant titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development," aimed at supporting exploratory research projects focused on radiation exposure and its medical countermeasures. The initiative seeks innovative proposals that address the development of biodosimetry techniques, medical countermeasures for radiation injuries, and animal model development, with an emphasis on high-risk, high-reward research that can enhance public health emergency preparedness. The total funding available is approximately $2 million, with individual awards capped at $100,000 per year for a maximum of two years. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" aimed at supporting collaborative research projects that address the long-term adverse effects of cancer therapies. The initiative seeks to identify and characterize the mechanisms behind therapy-induced adverse sequelae, with a focus on developing therapeutic strategies to prevent or mitigate these chronic comorbidities. This funding opportunity is crucial for enhancing patient quality of life through effective interventions based on mechanistic insights and clinical findings. Interested applicants, including various educational and community organizations, must submit their proposals by November 5, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at advancing cancer treatment through innovative nanotechnology-based diagnostics and therapeutics. This initiative supports advanced pre-clinical research focused on developing nanoparticle and nano-device interventions that enhance the effectiveness of cancer treatments, particularly in combination therapy, immunotherapy, and imaging. The program emphasizes multidisciplinary collaboration and requires proposals to outline clear milestones for project advancement, with a maximum budget of $475,000 in direct costs annually over a project period of up to four years. Interested applicants must submit their proposals by November 17, 2024, and can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a funding opportunity announcement for a cooperative agreement aimed at establishing a Network Radiotherapy and Imaging Core Services Center under the NCI National Clinical Trials Network (NCTN). This center will provide essential scientific and technical expertise for quality control, assurance, and image data management in NCTN trials that involve radiotherapy and imaging modalities, as well as support for other NCI-supported clinical trial programs. The funding opportunity is significant for enhancing cancer treatment research and is expected to have a total program funding of $8.8 million, with a ceiling of $8.14 million for the award. Interested private institutions of higher education should prepare their applications, as the anticipated application due date is in late February 2025, with an estimated award date set for March 1, 2026.
    STrengthening Research Opportunities for NIH Grants (STRONG): Structured Institutional Needs Assessment and Action Plan Development for Resource Limited Institutions (RLIs) (UC2 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the STrengthening Research Opportunities for NIH Grants (STRONG) program, which focuses on conducting structured institutional needs assessments and developing action plans for Resource Limited Institutions (RLIs). The initiative aims to enhance the research capacity of RLIs, which serve historically underrepresented populations in biomedical research and have received NIH support of $0 to $25 million annually over the past three fiscal years. This program is crucial for improving competitiveness for NIH funding and fostering research career development in diverse environments. Eligible institutions can apply for a maximum budget of $250,000 annually for a project period of three years, with applications due by September 18, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.